A high serum concentration of YKL-40 is emerging as a new biomarker of severe disease activity and poor prognosis in patients with diseases characterized by inflammation and ongoing tissue remodelling such as RA, inflammatory bowel disease, asthma and cancer [8,10,16-26]. This evidence concerns the gene CHI3L1 and rheumatoid arthritis.